FDA allows uniQure to seek accelerated approval for Huntington's disease therapy

Jun 18, 2026, 3:57 PM10

(Update: Jun 18, 2026, 3:57 PM)

FDA Records

German record label

science

informative

impactful

FDA allows uniQure to seek accelerated approval for Huntington's disease therapy

The FDA has reversed its previous decision and will allow uniQure to pursue accelerated approval for AMT-130.
Huntington's disease affects up to 40,000 Americans and is characterized by severe neurodegenerative symptoms.
This decision has been celebrated by the rare disease community, offering hope for new treatment options.

FDA Records

German record label

Insights

News 1

Related reports

Opinions

Story

“

trends global impact analysis market economic insight shift analysis shift impact impact shift economic shift global data analysis trends insight analysis data economic global strategic strategic market data insight data data global policy analysis policy insight trends analysis data impact insight geopolitical analysis strategic economic data market geopolitical analysis shift geopolitical data shift economic global economic strategic strategic economic impact market policy strategic trends shift insight economic geopolitical global shift trends shift global economic insight impact market strategic impact shift...